Roger Sawhney

CIK: 0001858748

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ABUS

Arbutus Biopharma Corp

Director

ANL

Adlai Nortye Ltd.

Director

ACTU

ACTUATE THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

ABUS
Arbutus Biopharma Corp
Oct 1, 2026
Disposition(D)
Direct
17.1K shares at avg. $5.00$86K
ABUS
Arbutus Biopharma Corp
Sep 18, 2026
Exercise(M)
Direct
52.5K shares at avg. $3.34$175K
ABUS
Arbutus Biopharma Corp
Sep 18, 2026
Exercise(M)
Direct
78.8K shares at avg. $4.24$334K
ABUS
Arbutus Biopharma Corp
Sep 18, 2026
Tax Payment(F)
Direct
100.5K shares at avg. $5.07$510K
ABUS
Arbutus Biopharma Corp
Jun 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
78.8K shares-
ACTU
ACTUATE THERAPEUTICS, INC.
May 21, 2026
Award(A)
Stock Options
Direct
15K shares-
ABUS
Arbutus Biopharma Corp
Aug 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
157.6K shares-
ACTU
ACTUATE THERAPEUTICS, INC.
May 22, 2025
Award(A)
Stock Options
Direct
15K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	ABUS Arbutus Biopharma Corp	Disposition(D)	17,142	$5.00	$85,710	Direct
Sep 18, 2026	ABUS Arbutus Biopharma Corp	Exercise(M)	52,533	$3.34	$175,460	Direct
Sep 18, 2026	ABUS Arbutus Biopharma Corp	Exercise(M)	78,800	$4.24	$334,112	Direct
Sep 18, 2026	ABUS Arbutus Biopharma Corp	Tax Payment(F)	100,508	$5.07	$509,576	Direct
Jun 8, 2026	ABUS Arbutus Biopharma Corp	Award(A) Stock Option (Right to Buy)	78,800	-	-	Direct
May 21, 2026	ACTU ACTUATE THERAPEUTICS, INC.	Award(A) Stock Options	15,000	-	-	Direct
Aug 4, 2025	ABUS Arbutus Biopharma Corp	Award(A) Stock Option (Right to Buy)	157,600	-	-	Direct
May 22, 2025	ACTU ACTUATE THERAPEUTICS, INC.	Award(A) Stock Options	15,000	-	-	Direct

1-8 of 8 transactions

About Sawhney Roger

Sawhney Roger (SEC CIK 0001858748) files insider reports with the SEC as Director of Arbutus Biopharma Corp (ABUS), Director of Adlai Nortye Ltd. (ANL) and Director of ACTUATE THERAPEUTICS, INC. (ACTU).

Signal8 holds 8 ownership filings by Sawhney Roger (2 Form 3, 6 Form 4), filed between May 23, 2025 and Oct 7, 2026. Those filings report 8 transactions, from May 22, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sawhney Roger's filings is in WARMINSTER, PA.

Recent filings by Sawhney Roger

Oct 1, 2026: Disposition to issuer transaction of ABUS shares (Form 4, code D).
Sep 18, 2026: Option exercises of ABUS shares (2 lines, Form 4, code M).
Sep 18, 2026: Tax withholding of ABUS shares (Form 4, code F).
Jun 8, 2026: Grant or award of ABUS derivative securities (Form 4, code A).
May 21, 2026: Grant or award of ACTU derivative securities (Form 4, code A).

Other insiders filing for Arbutus Biopharma Corp (ABUS)

Beardsley Robert A, Director
Nguyen Tuan, Chief Financial Officer
Androski Lindsay, President and CEO
Hasija Anuj, Director
Bishop Joseph E, Director
Gline Matthew, Director

How to read Form 4 transaction codes